Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
25 avr. 2023 18h00 HE
|
Achilles Therapeutics PLC
LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
25 avr. 2023 07h00 HE
|
Achilles Therapeutics PLC
- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient’s tumor - - Patent applies to any modality, including vaccine and...
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
17 avr. 2023 08h00 HE
|
Achilles Therapeutics PLC
LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid...
Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
07 mars 2023 07h00 HE
|
Achilles Therapeutics PLC
- Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients - - Exhibited power of translational science platform by correlating anti-tumor activity of cNeT...
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
20 déc. 2022 08h30 HE
|
Achilles Therapeutics PLC
LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors,...
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
06 déc. 2022 06h00 HE
|
Achilles Therapeutics PLC
- Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC - - Safety and tolerability...
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
30 nov. 2022 18h05 HE
|
Achilles Therapeutics PLC
- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - - Updated interim Phase I/II results...
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
22 nov. 2022 08h00 HE
|
Achilles Therapeutics PLC
LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors,...
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
08 nov. 2022 07h00 HE
|
Achilles Therapeutics PLC
- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 - - Strong cash balance of...
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
06 oct. 2022 08h30 HE
|
Achilles Therapeutics PLC
Professor Swanton joins Achilles SAB member Dr. Christopher Klebanoff and Dr. John Haanen on the key opinion leader panel to discuss neoantigens as valuable immunotherapy targets Virtual Roundtable...